FlorianSEichlerMD

"Associate Professor of Neurology, Harvard Medical School Assistant in Neurology, Massachusetts General Hospital Director, Leukodystrophy Clinic Director, Center for Rare Neurological Diseases"

Join to view full profile

Dr. Eichler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Eichler's full profile

Already have an account?

Office
55 Fruit St
# YAW6B
Boston, MA 02114
Phone+1 617-726-6093

Fax+1 617-726-2019

Education & Training

Massachusetts General HospitalFellowship, Child Neurology, 2002 - 2005
Geisinger Health SystemResidency, Pediatrics, 2001 - 2002
University of Vienna Faculty of MedicineClass of 1997

Certifications & Licensure

MA State Medical License 2005 - 2026
PA State Medical License 2001 - 2002
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology

Awards, Honors, & Recognition

Champion of Hope in Rare Diseases Global Genes, 2015
Teacher of the Year Award in Child Neurology Massachusetts General Hospital, 2013
Clinical Research Day Departmental Award for Neurology Massachusetts General Hospital, 2011
Wolfe Neuropathy Research Prize American Neurological Association, 2009
Join now to see all

Clinical Trials

A Natural History Study of the Gangliosidoses Start of enrollment: 2010 Dec 01
Recruiting
L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1 Start of enrollment: 2013 Sep 01
Completed
Phase 1, Phase 2
A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD) Start of enrollment: 2013 Aug 21
Completed
Phase 2, Phase 3
A Natural History Study of Canavan Disease Start of enrollment: 2016 May 01
Completed
A Natural History of Late Onset Tay-Sachs Disease Start of enrollment: 2016 Apr 01
Active, not recruiting
A Dose-escalation and Safety & Efficacy Study of AXO-AAV-GM2 in Tay-Sachs or Sandhoff Disease Start of enrollment: 2021 Jan 15
Active, not recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Anandefficacy evaluation of gene therapy candidate SBT101 in mouse models of adrenomyeloneuropathy and in NHPs.
Vidyullatha Vasireddy, Casey A Maguire, David W Anderson, Carrie Ng, Yi Gong
Molecular Therapy. Methods & Clinical Development. 2024-12-12
Urine-Acetylaspartate Distinguishes Phenotypes in Canavan Disease.
Amanda Nagy, Florian Eichler, Annette Bley, Janna Bredow, Alexander Fay
Human Gene Therapy. 2024-12-04
Characterizing visual processing deficits in cerebral adrenoleukodystrophy.
Camille S Corre, Melissa Bambery, Christopher R Bennett, Amanda Nagy, Claire E Manley
Brain & Development. 2024-11-01

Press Mentions

NEJM Reports Detail Blood Cancers After Gene Therapy for Cerebral AdrenoleukodystrophyOctober 16th, 2024
Gene Therapy for Adrenoleukodystrophy: Studies Find Both Risks and BenefitsOctober 16th, 2024
Report Gives Update on Boys with Rare Brain Disease 6 Years After Gene TherapyOctober 10th, 2024
Join now to see all

Grant Support

The Role Of Desoxysphingoid Bases In Hsan1National Institute Of Neurological Disorders And Stroke2011–2012
1-Deoxydihydroceramides In Hereditary Sensory &Autonomic Neuropathy Type INational Center For Research Resources2011
Imaging The Pathophysiology Of AMN In Mice And HumansNational Institute Of Neurological Disorders And Stroke2006–2010